These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1384 related articles for article (PubMed ID: 21952978)

  • 1. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Tanaka Y; Suzuki M; Nakamura H; Toyoizumi S; Zwillich SH;
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1150-8. PubMed ID: 21584942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
    Fleischmann R; Kremer J; Cush J; Schulze-Koops H; Connell CA; Bradley JD; Gruben D; Wallenstein GV; Zwillich SH; Kanik KS;
    N Engl J Med; 2012 Aug; 367(6):495-507. PubMed ID: 22873530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
    Tanaka Y; Maeshima K; Yamaoka K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate.
    Mease P; Strand V; Shalamberidze L; Dimic A; Raskina T; Xu LA; Liu Y; Smith J
    Ann Rheum Dis; 2012 Jul; 71(7):1183-9. PubMed ID: 22328739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
    Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
    J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.
    Fleischmann RM; Damjanov NS; Kivitz AJ; Legedza A; Hoock T; Kinnman N
    Arthritis Rheumatol; 2015 Feb; 67(2):334-43. PubMed ID: 25385260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
    van der Heijde D; Tanaka Y; Fleischmann R; Keystone E; Kremer J; Zerbini C; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Wyman BT; Gruben D; Benda B; Wallenstein G; Krishnaswami S; Zwillich SH; Bradley JD; Connell CA;
    Arthritis Rheum; 2013 Mar; 65(3):559-70. PubMed ID: 23348607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
    Rigby W; Tony HP; Oelke K; Combe B; Laster A; von Muhlen CA; Fisheleva E; Martin C; Travers H; Dummer W
    Arthritis Rheum; 2012 Feb; 64(2):350-9. PubMed ID: 21905001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.
    Tanaka Y; Takeuchi T; Yamanaka H; Nakamura H; Toyoizumi S; Zwillich S
    Mod Rheumatol; 2015 Jul; 25(4):514-21. PubMed ID: 25496464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.